Answers are grounded in this paper and cite their sources.
Tuberculosis, a predominant disease in the nineteenth century, remains one of the most life-threatening diseases at the beginning of the new millennium. It causes two million deaths per year. The incidence of the disease has been always high in developing countries. However, its re-emergence in industrialized countries is a major public health problem and was completely unexpected by the general public, researchers, doctors and the authorities. Nobody could have predicted that tuberculosis would strike again, despite the continuous decline in the incidence of tuberculosis between 1800 and 1950, the development of effective antituberculosis drugs, and improvements in public health and living conditions. What went wrong? Or, perhaps, why did things go wrong? And, of course, what can we do to control tuberculosis now and in future? Hopefully, we now know more about tuberculosis than in the nineteenth century, when the fresh air of the mountains was the only prescription available, as Thomas Mann beautifully described in The Magic Mountain. In 1993 the World Health Organization declared that tuberculosis was a global health emergency. Since this time, considerable effort has improved our knowledge on the biology of these bacilli and their interactions with humans. Studies on this pathogen revealed new pathways involved in antigen presentation and T-cell recognition. Genetic tools were used to identify virulence genes. The availability of several mycobacterial genome sequences might elucidate host–pathogen interactions. Thus, knowledge of the human genome sequence will provide new tools for intervention. The Juan March Workshop on Molecular Approaches to Tuberculosis (Madrid, 11–13 December 2000) brought together many researchers from around the world to discuss the current understanding of tuberculosis from a molecular point of view, and the perspectives for tackling this disease. The genome, genetic analysis, the ultrastructure of the cell wall, mechanisms of drug resistance, strategies for developing new drugs, strategies for survival within infected cells, relevant mycobacterial antigens, virulence determinants, induced alterations in cytokine circuits, host–pathogen interactions and vaccine development were discussed. Molecular knowledge of a bacterium and its host is essential for the control of a disease. However, to consider a bacterium just a compendium of molecules and to consider a disease only in terms of molecular interactions is too simplistic and not totally realistic. Douglas Young (Imperial College, London, UK) emphasized the social and economical implications of tuberculosis, a highly transmissible disease. Curing one patient can prevent many other people from getting infected. An infected individual's particular susceptibility (owing to genetic and nutritional causes, whether they have been vaccinated and their immune status) will determine whether they will develop the disease. As one third of the world's population is believed to be infected with the tubercle bacillus, the risk of developing an active disease after infection is a crucial issue. Our immediate objective is to cure patients with active tuberculosis and the next stage will be to reduce the probability of developing the disease after infection, for example, using a vaccine. Social and economic factors are as important as molecular approaches, and the final solution will include all of these aspects. Stewart Cole (Institut Pasteur, Paris, France) summarized the main features of the Mycobacterium tuberculosis H37Rv genome. It contains approximately 4000 putative genes (of which 60% have a predicted function) that provide M. tuberculosis with a wide range of metabolic pathways, including those for aerobic, microanaerobic and anaerobic metabolism (Cole et al., 1998). Lipid metabolism involves many genes, as predicted by the complexity and diversity of lipid content in the mycobacterial cell wall. M. tuberculosis has a high number of regulatory genes, indicating that it must be highly adaptable to changing conditions, consistent with the environmental origins of the mycobacteria, which only became a human pathogen about 15 000 years ago (Sreevatsan et al., 1997). Many repetitive genes, mostly of unknown function, such as members of the PE and PPE families, may be related to antigenic variation, conferring plasticity to both the genome and the bacillus. Other mycobacterial genomes (M. leprae, M. tuberculosis CDC1551 and 210, M. bovis AF2122/97 and BGC-Pasteur, M. smegmatis, M. avium and M. paratuberculosis) have now been either completely sequenced or will be soon. Genome comparisons may expand our knowledge on the molecular bases of pathogenicity, virulence and host specificity, and evolutionary aspects may also be revealed. Libraries of BAC-arrays (Gordon et al., 1999; Brosch et al., 2000) and DNA microarrays (Behr et al., 1999) have been used for genome comparisons. To date, five deletions (RvD1-RvD5) have been detected in the genome of M. tuberculosis H37Rv in comparison with M. bovis genome, and at least 16 deletions (RD1-RD16) have been detected in the chromosome of the Pasteur substrain of the vaccine strain M. bovis BCG. The distribution of these deletions among species of the M. tuberculosis complex has established new evolutionary relationships, suggesting that M. tuberculosis, M africanum, M. microti, M. bovis and M. bovis BCG appeared sequentially from a common ancestor. This rules out the hypothesis of human tuberculosis having a bovine origin. M. leprae was long thought to have been mistakenly included in the genus Mycobacterium, because of its low G + C content (58%). Stewart Cole showed that the 3.2 Mb genome of M. leprae (Cole et al., 2001) contains around 1600 genes, most of which are similar to M. tuberculosis genes. These 1600 genes can be considered as the minimal gene content for pathogenicity. M. leprae has a large number of pseudogenes, i.e. genes with premature stop codons or frameshift mutations in comparison with the M. tuberculosis counterparts. The scarcity of genes prevents M. leprae from using many metabolic pathways, especially those involved in catabolism and NADH utilization. This explains why this species has become an obligate intracellular organism and cannot grow on culture media. Many research projects have benefited from having the M. tuberculosis genome readily available on the tip of your keyboard, e.g. L. E. Quadri (Cornell University, New York, NY, USA) used genome information to describe the first steps of the mycobactin biosynthesis, the siderophores produced by M. tuberculosis (Quadri, 2000). For pathogens living and infecting mammalian hosts (such as M. tuberculosis), iron becomes an extremely precious metal (how many alchemists would have dreamed the same!) and siderophores are essential compounds that help the bacteria to get this nutrient from the mammalian iron-binding proteins. The M. tuberculosis genome project revealed a 25 kb cluster encoding the enzymes involved in the biosynthesis of the salicyl-capped peptide-polyketide scaffold of mycobactins. Some of these enzymes have been successfully expressed in M. smegmatis, and the salicylation and phosphopantetheinylation reactions have been characterized in vitro. Mycobactin biosynthesis is an attractive target for the development of new drugs or the construction of new vaccines because mycobactins are essential for M. tuberculosis growth inside macrophages (De Voss et al., 2000). The choice of genetic tools for analysing gene function is probably as important as having access to complete genome sequences. In recent years, there has been much progress in the development of tools such as plasmid and phage vectors, transposons, reporter genes and strategies for gene inactivation and mutagenesis (Hatfull and Jacobs, 2000). Currently, the aim of most genetic studies on mycobacteria is to find virulence genes (this was probably one of the objectives of the genome project itself), and the genetic tools developed in the last 10 years are being used to reach this goal. C. Guilhot (Institut Pasteur, Paris, France) described the use of signature-tagged transposon mutagenesis (a technology successfully used in the study of other human pathogens; Hensel et al., 1995) to generate M. tuberculosis mutants and the selection of mutants with growth attenuated in mice during the first 3 weeks of infection (Camacho et al., 1999). Not surprisingly, in most of the mutants the transposon was inserted into genes involved in lipid metabolism, emphasizing the importance of this kind of molecule for mycobacterial pathogenesis. Four of these mutations affected a 50 kb region of the chromosome that contains polyketide synthase and the transporter genes involved in the biosynthesis and transport of phtiocerol dimycoserosate (DIM), a lipid found in the outer layer of the mycobacterial envelope. As well as being attenuated, these mutants were more permeable to hydrophobic compounds, such as chenodeoxycholate, and more sensitive to detergents (Camacho et al., 2001). These findings indicate that extractable lipids are important for maintaining the permeability of the barrier and for bacterial virulence, perhaps by modulating the host's immune response. Mycobacteriophages have played a major role in the development of mycobacterial genetics. They were the first system available for transforming mycobacteria. Many different mycobacteriophages have now been isolated and sequenced, a large number of phage-derived vectors have been constructed and many clinical and research techniques rely on them. In addition, as Bill Jacobs reported, it seems that new isolates can be isolated very simply, for example, from soil samples. Manipulated mycobacteriophages containing, for example, the luciferase reporter gene, are a rapid, simple and reliable method for assessing drug resistance in mycobacteria. Specialized transducing phages can be used as an alternative strategy to construct knockout mutants in mycobacteria. The continuous development of genetic tools should enable us to address the complex questions surrounding mycobacterial interactions with humans. One of these problems is drug resistance, because only a limited number of drugs are active against mycobacteria. The catalase–peroxidase the et al., M. tuberculosis clinical isolates mutations or deletions in the gene studies have that these mutations to virulence in et al., 1998). However, isolates were found to be to both and patients not been with This that and might a common Bill Jacobs of NY, USA) the of this target in M. as the of the gene, an similar to et al., indicating that probably with NADH to which and The the synthase biosynthesis, and in the of the produced by other mycobacterial which must be for M. the inactivation of a in the of also M. et al., 2000). M. tuberculosis also has an gene, other for have been in this such as the of the gene and an also involved in et al., 1998). As most M. tuberculosis isolates have alterations in than in the a study of the for is an attractive because it could to the development of new drugs that the enzymes would To the of drug resistance in M. tuberculosis, one of the most is the of new developed techniques have the and of new and DNA is a antituberculosis it the biosynthesis of both and by to and cell et al., et al., 2000). in the genes, which have been with of USA) used DNA microarrays to identify genes and their were to luciferase gene et al., This construction was into M. tuberculosis and used to a of and for compounds that produced This new that are being for their against M. tuberculosis, both in and in in and also for their against M. tuberculosis are being out with other molecules the new of antituberculosis compounds for the of this disease et al., described mycobacterial drug resistance, of resistance and and their implications for mycobacterial resistance is produced by mutations than by the of drug inactivation mechanisms transmissible or isolates by sequentially mutations in genes. the mutations in M. tuberculosis isolated from patients do not to in terms of bacterial et al., which that isolates do not have a and will in the as well as the drug susceptibility in mycobacteria is mostly for a of a the of to this However, this method cannot different of resistance, which the of the mutations for example, or This range of resistance may why more than one third of of tuberculosis by can be by et al., 2000). do not between different mutations probably different of the resistance and may prevent new drug isolates from and reduce the number of the in tuberculosis in et al., 2001) and showed that very is about the genetic of these In the and of have been described in human of these have been well characterized at molecular for the strain that to the et al., by similar have been described in and and are common in et al., 1999). In most are to and most M. tuberculosis were not to other However, one particular strain of M. bovis has been isolated in more than of mostly in patients et al., 2001). with other M. bovis the strain many including of the bacilli and suggesting regulatory Genetic of the strain revealed that one of the two of the sequence is inserted of the global its that is involved in M. tuberculosis virulence has been et al., 2001). Molecular have been used to determine whether of are by particular with unknown as in the of the in the or M. bovis in These findings that particular M. tuberculosis complex are for than The and complex mycobacterial cell has always been one of the major for mycobacteria and for the use of antituberculosis However, important have been understanding the genetic of the biosynthesis of cell and of the pathways to their This has both and to their on using the cell to develop new drugs and University, USA) our understanding of the mycobacterial cell has the cell and the in which they are have been for many years, the of the cell has in recent In the the in a of the cell and that their were to the a highly hydrophobic to the outer of the which are and to the This has been to new cell and features as they were and to the of a new in which both and are into to the et al., 2000). The new the of cell and the between them. It that are which may the of the mycobacterial cell and the resistance to The low permeability of the mycobacterial cell may also a low of which are probably species et al., 1999). from in M. tuberculosis are to the a involved with the of the a that has been related with Bill Jacobs described the of the M. tuberculosis gene, which is involved in the of of causes alterations in and of and and virulence et al., 2000). As can be to the immune system by antigens, alterations in their will probably the interactions with For the cell its interactions with the In mycobacteria, are the immediate inside infected mycobacterial cell with the they and many (such as cytokine and T-cell by with host cell to be involved in mycobacteria. (Institut et France) for example, can Mycobacterium in et al., 2000). This is by 3 which is with proteins. are in of the which are in The of M. by is both by the of in the and with C. of USA) and of USA) the role of in the of mycobacteria by macrophages and the of of such as et al., 1999; et al., 2001). which the immune against in In these are by in which they identify bacteria and as a cell from and bacteria of In the of M. tuberculosis, to a other such as several cell such as the complex and the This which the of the seems to be a that the of which is to the of several including and a which intracellular mycobacteria. also showed infected macrophages mechanisms et al., 2001). The of by the of the synthase in This in the that the growth of intracellular mycobacteria. However, in human macrophages the of is not This that human macrophages have an of and in macrophages not in human However, these findings do not the that a role in the first involved in the et al., 1997). in more and 1999). bacteria are to the cell and them. Many host are involved in and their inactivation the at different For example, the inactivation of completely not the of However, the is when the bacterium is One of the features of mycobacterial survival within macrophages is their to intracellular which bacteria to and in the control mycobacteria can this to their In mycobacteria, a 50 was this was not detected in mycobacteria et al., 1999). This was because it contains five and is in the of macrophages at the of bacterial and in mycobacteria remains at this for of However, when mycobacteria are used to the from the within a of infection, indicating that mycobacteria are for the are in the role of for mycobacteria. for that the of to the is because when are with the is from the and 2000). of from macrophages in a of mycobacterial with in this did not the of other bacterial These findings that is essential for mycobacteria because it the of mycobacteria into macrophages and the of to which mycobacteria from M. tuberculosis infection, the between the survival and growth of the organism and the and of the host immune determine the of the disease. The immune involves a large number of interactions between cells, by the and of several seems to a M. tuberculosis isolates in terms of their growth virulence and to cytokine et al., 1999). the of the immune system may from to by As a a number of may of infected will develop an active disease in the the disease will have different of University, New York, NY, USA) on the between the bacilli and mice infected with the more to T-cell and In a of both and antigen the T-cell and The study of cell of M. tuberculosis isolates with different of virulence to the of the and lipids for the of cytokine cytokine may be considered to be a it is not after infection, pathways may to University, USA) that M. tuberculosis can cytokine in many different either a or an of In infected the tubercle the of transforming growth infected the T-cell and the of that can be detected by of by use of et al., 2000). the of is and the of to mycobacteria the of which the host immune and to the growth and survival of mycobacteria in the the of several genes are also within the mycobacterial infection, and may mycobacterial metabolism and gene In the of of the mycobacterial antigen an involved in cell biosynthesis, the presentation of this antigen to the immune the of which in by infected The of the of antigen in mycobacterial and the of the of antigen et al., 2001). The survival of mycobacteria within macrophages on their to to and the (Cornell University, NY, USA) several strategies used by M. tuberculosis in its to the and changing within are in mammalian and are by intracellular bacteria the and the and for other such as studies have revealed that in M. tuberculosis the of gene, encoding a is the infection of macrophages et al., 2000). The of is also induced by An of M. tuberculosis showed in growth during the of infection, in comparison with However, the was as infection The also attenuated These indicate that is essential for a The mycobacterial molecules during the and these molecules to as the the macrophages are by the which mycobacterial and the immune et al., 2000). However, this can be by mycobacteria, which to in the host mycobacteria a large of cell lipids that are into the host cell and into the These lipids prevent the from being by and the of the which prevents the from the of infection et al., 2000). It is that the immune of a response. However, against mycobacteria also involves other of France) described the role of the cells, which are the predominant population in in and the and T-cell of several compounds produced by can et al., 2000). This is not it involves interactions with the the molecules such as that As it not antigen and the of to the immune against tuberculosis probably during the of infection et al., 2000). can be to by of the five a kind of molecules are expressed by infection, that or These the infected and to control the similar which are by are also infected with M. tuberculosis, as by for London, UK) et al., 2000). of these are in (such as and the and low of molecules and However, infection they become and The the of several and other to in which they will to the T-cell response. M. are to mice against tuberculosis, as by the high of and produced in to antigen As the immune a large number of cell interactions in the in which infected macrophages and different of for a of University, USA) the and of the different cell in a et al., 2001). the infection than the number of and in the within are of are predominant the number of cells, which are at the of the These the a number of can also be detected in the In of tuberculosis has a particular of This is by the virulence of M. tuberculosis several factors may also to and from a more mycobacterial disease. The described human genetic that the to or to to As these alterations cytokine that are essential for the control of the patients were to mycobacterial and et al., 1998). These cytokine et al., 2000). In conditions, infected macrophages and that by and This in mechanisms in the which control and the intracellular or to mutations or deletions in the of the gene infection with mycobacteria or species of low pathogenicity. In these of and are In patients with for by a the and the of the have of do not to with may have for by the vaccine strain M. bovis BCG et al., 2000). These patients have a in the of and are to An to the has been As well as genetic other factors that the of the immune system must be patients have more disease mycobacterial because they target of the immune system for of immune patients are to mycobacterial infection, especially by M. avium or M. The high of M. has the tuberculosis for and USA) suggesting that there is a between both which that the of either pathogen the of the of is the common that to the of these to the of the different of the BCG a new of vaccines against tuberculosis is can be used to develop new one of which is the use of The antigen to a of in M. tuberculosis culture that the to the of in mice and et al., 2000). the antigen is with an of it a immune of as well as the BCG is antigen et al., that is a vaccine because it has been to in that a vaccine constructed by antigen to the a immune in conferring high of similar to those by BCG vaccine et al., 2000). This that for at least It has been that an important role in the immune response. For example, showed that the presentation to cells, and that the are by are with and in many the antigenic are as a of the These and other findings have the of as new vaccine because they may against progress has been in the development of and of which have very in However, the is to a vaccine that is than the used M. bovis BCG An alternative involves the of new attenuated vaccine or new BCG Thus, the development of genetic tools and information on virulence and could to the construction of and with than BCG. The in this Workshop that we have progress in understanding the biology of tuberculosis from a molecular point of and that we are now to study tuberculosis in in to and in studies will be with new tools from molecular The are to and from Juan March for the of this Workshop and for such a for among all have been in this are also to the have on and this is a of a from the of and to the research project Tuberculosis vaccine cluster
No takes yet. Share an insight, caveat, or question.
Aı́nsa et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: